Telephone: 01903 243351
Fax: 01903 705804
Cancellation Line: 01903 705855 (Please leave a message)
ALERTS!
Medication Alerts
The following medication is currently having supply issues, please take this into consideration when ordering your next prescription.
| Medication | Strength | How is it affected? | Information from | Recommendation | Date |
|---|---|---|---|---|---|
| Fluoxetine | 10mg, 20mg and 40mg | Serious Shortage. May affect the prescription and access to the drug. | Local Medical Committee | Please consult your GP | 07/10/19 |
| Emerade – PL 33616/0013, PL 33616/0014, PL 33616/0015 | 150, 300 and 500 microgram solution for injection in pre-filled syringe | Potential for units on the market to have a blockage of the needle which could lead to Emerade failing to deliver a dose when activated is estimated to be 0.23 %, which would affect 2.3 in every thousand pens
The risk of needle blockage is expected to be resolved in all new stock manufactured since July 2019. |
MAHRA | It is recommended for patients who may require the use of an adrenaline pen to carry two pre-filled syringes. | 04/10/19 |
| Ranitidine All Oral Formulation. | Ranitidine 75mg, 150mg and 300mg tablets • Ranitidine 150mg and 300mg effervescent tablets • Ranitidine 150mg/5ml oral solution • Ranitidine 75mg/5ml oral solution |
An investigation by the Swiss and German regulatory agencies and the FDA, has identified a contaminant, Nnitrosodimethylamine (NDMA), a probable human carcinogen, in samples of ranitidine active substance. Several ranitidine products manufactured for the UK market may contain this active substance contaminated with NDMA. The MHRA has requested that all UK manufacturers using active ingredient from this source quarantine all stock whilst further investigations are ongoing. To date, one supplier, GSK, has undertaken a Class 2 recall of all their ranitidine products. MHRA is continuing to investigate the issue alongside the European Medicines Agency (EMA). Currently all but three UK manufacturers are affected by this situation, however this may change as the MHRA and EMA continue their investigations. There are insufficient supplies available from the unaffected manufacturers to continue to support current usage of oral ranitidine in the UK. Very limited supplies of unaffected oral ranitidine products may remain available and therefore the majority of patients will need to be switched to alternative products. This issue is affecting supplies globally. |
MHRA | Please consult your GP | 16/10/2019 |
If you have any questions about the above, please contact the surgery (after 11 am) or speak to a local pharmacy.
